Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRY018
MIFTS: 48

Laryngeal Squamous Cell Carcinoma

Categories: Cancer diseases, Oral diseases, Respiratory diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Laryngeal Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Laryngeal Squamous Cell Carcinoma:

Name: Laryngeal Squamous Cell Carcinoma 12 56 15 17
Epidermoid Carcinoma of the Larynx 12
Squamous Cell Carcinoma of Larynx 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Skin diseases Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2876
NCIt 51 C4044
UMLS 74 C0280324
Sources

Summaries for Laryngeal Squamous Cell Carcinoma

About this section
Disease Ontology : 12 A laryngeal carcinoma that has material basis in squamous cells.

MalaCards based summary : Laryngeal Squamous Cell Carcinoma, also known as epidermoid carcinoma of the larynx, is related to squamous cell papilloma and squamous cell carcinoma. An important gene associated with Laryngeal Squamous Cell Carcinoma is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Cisplatin and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include lymph node, breast and skin, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Laryngeal Squamous Cell Carcinoma

About this section

Diseases related to Laryngeal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 30.7 AURKA CDKN2A TP53
2 squamous cell carcinoma 30.5 CCND1 CDH1 CDKN2A CDKN2B-AS1 EGFR H19
3 intrahepatic cholangiocarcinoma 30.3 CCAT1 CDH1 EGFR TP53
4 larynx cancer 30.1 CCND1 CDKN2A EGFR MIR21 NME1 TERT
5 adenocarcinoma 29.9 CCND1 CDH1 CDKN2A EGFR H19 MALAT1
6 thyroid cancer, nonmedullary, 1 29.9 H19 HOTAIR MALAT1 NEAT1
7 retinoblastoma 29.8 CCAT1 CCND1 CDKN2A HOTAIR MALAT1 TP53
8 melanoma 29.4 CDKN2A CDKN2B-AS1 H19 HOTAIR MALAT1 TP53
9 cholangiocarcinoma 28.8 CCND1 CDH1 CDKN2A EGFR H19 MALAT1
10 thyroid cancer 28.6 CCND1 CDH1 CDKN2B-AS1 EGFR H19 HOTAIR
11 nasopharyngeal carcinoma 27.8 CCAT1 CCND1 CDH1 CDKN2A CDKN2B-AS1 EGFR
12 breast papillomatosis 10.5 CCND1 CDKN2A
13 brain ependymoma 10.5 EGFR TP53
14 tonsil squamous cell carcinoma 10.5 CCND1 CDKN2A
15 cerebral convexity meningioma 10.4 CDH1 TP53
16 male reproductive system disease 10.4 CCND1 CDH1 TP53
17 bladder squamous cell carcinoma 10.4 CDKN2A TP53
18 oral leukoplakia 10.4 CCND1 CDKN2A TP53
19 verrucous carcinoma 10.4 CCND1 CDKN2A TP53
20 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
21 malignant peritoneal mesothelioma 10.4 CDKN2A EGFR
22 inverted papilloma 10.4 CCND1 CDKN2A TP53
23 retinal cancer 10.4 CCND1 CDKN2A TP53
24 hidradenocarcinoma 10.4 CCND1 EGFR TP53
25 basaloid squamous cell carcinoma 10.4 CDKN2A EGFR TP53
26 tongue disease 10.4 CDH1 CDKN2A TP53
27 vulva cancer 10.4 CDKN2A EGFR TP53
28 ocular cancer 10.4 CCND1 CDKN2A TP53
29 tonsil cancer 10.4 CDH1 CDKN2A TP53
30 bowenoid papulosis 10.4 CCND1 CDKN2A TERT
31 anaplastic oligodendroglioma 10.4 CDKN2A EGFR
32 estrogen-receptor positive breast cancer 10.4 CCND1 EGFR TP53
33 skin carcinoma in situ 10.4 CCND1 CDKN2A
34 cholecystitis 10.4 CDH1 CDKN2A TP53
35 recurrent respiratory papillomatosis 10.4 EGFR TP53
36 small cell carcinoma 10.4 CDKN2A EGFR TP53
37 spitz nevus 10.4 CDKN2A TP53
38 cervical squamous cell carcinoma 10.4 CDH1 CDKN2A TP53
39 grade iii astrocytoma 10.4 CDKN2A EGFR TP53
40 central nervous system cancer 10.4 CDKN2A EGFR TP53
41 soft tissue sarcoma 10.4 EGFR TERT TP53
42 male reproductive organ cancer 10.4 CCND1 CDH1 TP53
43 malignant peripheral nerve sheath tumor 10.4 CDKN2A EGFR TP53
44 bile duct cancer 10.4 CCND1 EGFR TP53
45 li-fraumeni syndrome 10.4 CDKN2A EGFR TP53
46 skin melanoma 10.4 CDKN2A NME1 TP53
47 triple-receptor negative breast cancer 10.3 HOTAIR MALAT1
48 penile cancer 10.3 CCND1 CDKN2A EGFR TP53
49 chordoma 10.3 CDH1 CDKN2A EGFR
50 esophageal disease 10.3 CCND1 CDKN2A EGFR TP53

Graphical network of the top 20 diseases related to Laryngeal Squamous Cell Carcinoma:



Diseases related to Laryngeal Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Laryngeal Squamous Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.62 AURKA EGFR
2 Decreased viability GR00221-A-1 9.62 AURKA CDH1 CDKN2A EGFR NME1
3 Decreased viability GR00221-A-2 9.62 AURKA NME1
4 Decreased viability GR00221-A-3 9.62 CDKN2A
5 Decreased viability GR00221-A-4 9.62 AURKA CDKN2A EGFR
6 Decreased viability GR00231-A 9.62 AURKA
7 Decreased viability GR00301-A 9.62 CDH1
8 Decreased viability GR00402-S-2 9.62 AURKA CDH1 CDKN2A EGFR NME1

MGI Mouse Phenotypes related to Laryngeal Squamous Cell Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 AURKA CCND1 CDH1 CDKN2A EGFR NME1
Sources

Drugs & Therapeutics for Laryngeal Squamous Cell Carcinoma

About this section

Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
3
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
4
Durvalumab Approved, Investigational Phase 2, Phase 3,Phase 1 1428935-60-7
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
7
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
8 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
9 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
10 Antibodies, Monoclonal Phase 2, Phase 3,Phase 3,Phase 1
11 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
12 Immunoglobulins Phase 2, Phase 3,Phase 3,Phase 1
13 Antibodies Phase 2, Phase 3,Phase 3,Phase 1
14 Antimitotic Agents Phase 3,Phase 2
15 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
16 Micronutrients Phase 3
17 Vitamins Phase 3
18 Trace Elements Phase 3
19 Immunoglobulin G Phase 2, Phase 3,Phase 3
20 Antimetabolites Phase 3,Phase 2,Phase 1
21 Angiogenesis Modulating Agents Phase 3,Phase 1
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
23 Endothelial Growth Factors Phase 3
24 Mitogens Phase 3
25 Angiogenesis Inhibitors Phase 3,Phase 1
26
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
27
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
29
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
30
Pembrolizumab Approved Phase 1, Phase 2,Phase 2 1374853-91-4
31
nivolumab Approved Phase 2 946414-94-4
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
34
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
35
leucovorin Approved Phase 2 58-05-9 143 6006
36
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
37
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
38
Trioxsalen Approved Phase 2 3902-71-4 5585
39
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
40
Cediranib Investigational Phase 2 288383-20-0 9933475
41
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
42
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
43 Albumin-Bound Paclitaxel Phase 2
44 Antineoplastic Agents, Phytogenic Phase 2
45 Omega 3 Fatty Acid Phase 2
46 arginine Phase 2
47 Soy Bean Phase 2
48 Anti-Infective Agents Phase 2
49 Anti-Bacterial Agents Phase 2
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
2 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
3 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
4 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer Completed NCT03067610 Phase 2 chemotherapy
5 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
6 A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer Completed NCT01314755 Phase 2
7 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
8 Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck Completed NCT01287390 Phase 2
9 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
10 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
11 A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma Recruiting NCT02759575 Phase 1, Phase 2 Pembrolizumab;Cisplatin
12 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Recruiting NCT03342911 Phase 2 Paclitaxel;Carboplatin
13 Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy Recruiting NCT03468218 Phase 2 Cabozantinib
14 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting NCT02734537 Phase 2 Cisplatin
15 Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer. Active, not recruiting NCT01341535 Phase 2
16 Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT01064479 Phase 2 Carboplatin;Cisplatin;Docetaxel;Erlotinib Hydrochloride
17 Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Active, not recruiting NCT00494182 Phase 2 Carboplatin;Paclitaxel;Sorafenib
18 IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma Not yet recruiting NCT03381183 Phase 1, Phase 2 Durvalumab;Tremelimumab;IRX-2 Regimen
19 A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy Terminated NCT01720563 Phase 2 Astragalus polysaccharides 500 mg;Placebo
20 Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Terminated NCT02196168 Phase 2 Cisplatin;WEE1 Inhibitor AZD1775
21 Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Terminated NCT01267240 Phase 2 Capecitabine;Vorinostat
22 Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer Terminated NCT02068157 Phase 2 Photodynamic Therapy;Porfimer Sodium
23 Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Active, not recruiting NCT01254617 Phase 1 Lenalidomide
24 Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin Active, not recruiting NCT02381535 Phase 1 Cisplatin;Onalespib
25 Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer Active, not recruiting NCT01935921 Phase 1
26 Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT02775812 Phase 1 Cisplatin
27 Ganetespib Window of Opportunity Study in Head and Neck Cancers Terminated NCT02334319 Phase 1 Ganetespib
28 ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
29 Altered and Conventional Fractionated Radiotherapy in Patients With Head and Neck Cancer Completed NCT00291434
30 Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers Completed NCT02035735 Not Applicable
31 Questionnaire in Screening Older Patients With Cancer Completed NCT00963911 Not Applicable
32 Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer Recruiting NCT03747783
33 Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer Recruiting NCT03595410
34 Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer Recruiting NCT03032250 Not Applicable
35 Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT02582008 Early Phase 1 Bupropion Hydrochloride;Nicotine Replacement;Varenicline
36 Wound Complications in Head and Neck Surgery Enrolling by invitation NCT03134976 Levothyroxine
37 Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer Terminated NCT02388932 Not Applicable

Search NIH Clinical Center for Laryngeal Squamous Cell Carcinoma

Sources

Genetic Tests for Laryngeal Squamous Cell Carcinoma

About this section
Sources

Anatomical Context for Laryngeal Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Laryngeal Squamous Cell Carcinoma:

42
Lymph Node, Breast, Skin, Thyroid, Lung, Prostate, Endothelial
Sources

Publications for Laryngeal Squamous Cell Carcinoma

About this section

Articles related to Laryngeal Squamous Cell Carcinoma:

(show top 50) (show all 913)
# Title Authors Year
1
p16 Influence on Laryngeal Squamous Cell Carcinoma Relapse and Survival. ( 30642220 )
2019
2
Combination of TPF regimen and cinobufotalin inhibits proliferation and induces apoptosis in human hypopharyngeal and laryngeal squamous cell carcinoma cells. ( 30643431 )
2019
3
LncRNA UCA1 promotes cell proliferation, invasion and migration of laryngeal squamous cell carcinoma cells by activating Wnt/β-catenin signaling pathway. ( 30679991 )
2019
4
Aberrant methylation and downregulation of ZNF667-AS1 and ZNF667 promote the malignant progression of laryngeal squamous cell carcinoma. ( 30684967 )
2019
5
Aurora kinase A induces chemotherapy resistance through revival of dormant cells in laryngeal squamous cell carcinoma. ( 30706572 )
2019
6
MMP2/3 promote the growth and migration of laryngeal squamous cell carcinoma via PI3K/Akt-NF-κB-mediated epithelial-mesenchymal transformation. ( 30714134 )
2019
7
Pretreatment albumin globulin ratio has a superior prognostic value in laryngeal squamous cell carcinoma patients: a comparison study. ( 30719156 )
2019
8
DIAPH1 Is Upregulated and Inhibits Cell Apoptosis through ATR/p53/Caspase-3 Signaling Pathway in Laryngeal Squamous Cell Carcinoma. ( 30733838 )
2019
9
Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience. ( 30782197 )
2019
10
DIAPH2 alterations increase cellular motility and may contribute to the metastatic potential of laryngeal squamous cell carcinoma. ( 30793164 )
2019
11
Wnt1-inducible signaling protein 1 regulates laryngeal squamous cell carcinoma glycolysis and chemoresistance via the YAP1/TEAD1/GLUT1 pathway. ( 30805937 )
2019
12
Long noncoding RNA SOX2-OT facilitates laryngeal squamous cell carcinoma development by epigenetically inhibiting PTEN via methyltransferase EZH2. ( 30811870 )
2019
13
Digital Analysis of BCL2 Expression in Laryngeal Squamous Cell Carcinoma. ( 30842155 )
2019
14
The long noncoding RNA ST7-AS1 promotes laryngeal squamous cell carcinoma by stabilizing CARM1. ( 30853182 )
2019
15
MicroRNA-101 regulates autophagy, proliferation and apoptosis via targeting EZH2 in laryngeal squamous cell carcinoma. ( 30868890 )
2019
16
Photoacoustic-imaging-guided therapy of functionalized melanin nanoparticles: combination of photothermal ablation and gene therapy against laryngeal squamous cell carcinoma. ( 30882835 )
2019
17
Seed and soil? - Pharyngeal Merkel cell carcinoma after radiotherapy for laryngeal squamous cell carcinoma. ( 30885449 )
2019
18
miR-506 is a YAP1-dependent tumor suppressor in laryngeal squamous cell carcinoma. ( 30907227 )
2019
19
MEG3 inhibits cell proliferation, invasion and epithelial-mesenchymal transition in laryngeal squamous cell carcinoma. ( 30915750 )
2019
20
Caspase complex in laryngeal squamous cell carcinoma. ( 30941944 )
2019
21
Telomerase activity in laryngeal squamous cell carcinoma. ( 30942000 )
2019
22
Zinc finger E‑box binding homeobox 2 functions as an oncogene in human laryngeal squamous cell carcinoma. ( 30957184 )
2019
23
Radiation Therapy Impact on Lymph Node Yield in Patients With Laryngeal Squamous Cell Carcinoma. ( 30961371 )
2019
24
Expression of vimentin (VIM) and metastasis-associated 1 (MTA1) protein in laryngeal squamous cell carcinoma are associated with prognostic outcome of patients. ( 30979652 )
2019
25
Clinical effect of postoperative chemoradiotherapy in resected advanced laryngeal squamous cell carcinoma. ( 30988826 )
2019
26
CircRASSF2 promotes laryngeal squamous cell carcinoma progression by regulating the miR-302b-3p/IGF-1R axis. ( 30992382 )
2019
27
ESRRG promoter hypermethylation as a diagnostic and prognostic biomarker in laryngeal squamous cell carcinoma. ( 31002184 )
2019
28
Combined EGFR/ALK Expression Analysis in Laryngeal Squamous Cell Carcinoma. ( 31028202 )
2019
29
Knockdown of FOXJ1 inhibits the proliferation, migration, invasion, and glycolysis in laryngeal squamous cell carcinoma cells. ( 31062413 )
2019
30
Significance of Cytokeratin-1 Single-Nucleotide Polymorphism and Protein Level in Susceptibility to Vocal Leukoplakia and Laryngeal Squamous Cell Carcinoma. ( 31067553 )
2019
31
Long noncoding RNA XIST increases the aggressiveness of laryngeal squamous cell carcinoma by regulating miR-124-3p/EZH2. ( 31071316 )
2019
32
TGF-β-induced long non-coding RNA MIR155HG promotes the progression and EMT of laryngeal squamous cell carcinoma by regulating the miR-155-5p/SOX10 axis. ( 31081043 )
2019
33
LncRNA SNHG20 promotes the development of laryngeal squamous cell carcinoma by regulating miR-140. ( 31081112 )
2019
34
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel. ( 31090975 )
2019
35
Positive BCL2L12 expression predicts favorable prognosis in patients with laryngeal squamous cell carcinoma. ( 31104007 )
2019
36
Integrated miRNA and mRNA expression analysis uncovers drug targets in laryngeal squamous cell carcinoma patients. ( 31109699 )
2019
37
Matrix metalloproteinases (MMPs) and inhibitor of metalloproteinases (TIMP) mRNA and protein expression in laryngeal squamous cell carcinoma. ( 31110546 )
2019
38
MicroRNA-4497 functions as a tumor suppressor in laryngeal squamous cell carcinoma via negatively modulation the GBX2. ( 29843929 )
2019
39
Tumor suppression effect of targeting periostin with siRNA in a nude mouse model of human laryngeal squamous cell carcinoma. ( 29978598 )
2019
40
Comprehensive analysis of the whole coding and non-coding RNA transcriptome expression profiles and construction of the circRNA-lncRNA co-regulated ceRNA network in laryngeal squamous cell carcinoma. ( 30128795 )
2019
41
Long noncoding RNA PVT1 promotes laryngeal squamous cell carcinoma development by acting as a molecular sponge to regulate miR-519d-3p. ( 30304557 )
2019
42
Promoter Methylation-Regulated miR-145-5p Inhibits Laryngeal Squamous Cell Carcinoma Progression by Targeting FSCN1. ( 30341010 )
2019
43
Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. ( 30361882 )
2019
44
Integrative analysis of mRNA and microRNA expression profiles in laryngeal squamous cell carcinoma. ( 30362598 )
2019
45
To investigate the affiliation of XRCC-1 Gene Arg194Trp polymorphism in alcohol and tobacco substance users and loco-regionally progressed Laryngeal squamous cell carcinoma. ( 30370213 )
2019
46
Expression profile analysis identifies the long non-coding RNA landscape and the potential carcinogenic functions of LINC00668 in laryngeal squamous cell carcinoma. ( 30415008 )
2019
47
Molecular mechanisms of apoptosis and autophagy elicited by combined treatment with oridonin and cetuximab in laryngeal squamous cell carcinoma. ( 30430397 )
2019
48
α2δ1 may be a potential marker for cancer stem cell in laryngeal squamous cell carcinoma. ( 30475757 )
2019
49
Spondin-2 is a novel diagnostic biomarker for laryngeal squamous cell carcinoma. ( 30527359 )
2019
50
MicroRNA‑143‑3p suppresses cell growth and invasion in laryngeal squamous cell carcinoma via targeting the k‑Ras/Raf/MEK/ERK signaling pathway. ( 30535502 )
2019
Sources

Variations for Laryngeal Squamous Cell Carcinoma

About this section

Cosmic variations for Laryngeal Squamous Cell Carcinoma:

9 (show top 50) (show all 322)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6927812 ZFHX3 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.4946C>T p.S1649F 16:72797736-72797736 0
2 COSM45571 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.593A>G p.E198G 17:7674938-7674938 0
3 COSM10714 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.473G>T p.R158L 17:7675139-7675139 0
4 COSM11066 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>T p.H193L 17:7674953-7674953 0
5 COSM11245 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.430C>T p.Q144* 17:7675182-7675182 0
6 COSM10779 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>T p.R273L 17:7673802-7673802 0
7 COSM10905 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 0
8 COSM43690 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.592G>A p.E198K 17:7674939-7674939 0
9 COSM10888 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.378C>A p.Y126* 17:7675234-7675234 0
10 COSM6549 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>T p.R248L 17:7674220-7674220 0
11 COSM10659 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
12 COSM10893 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.824G>A p.C275Y 17:7673796-7673796 0
13 COSM44475 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.871A>T p.K291* 17:7673749-7673749 0
14 COSM10813 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.394A>G p.K132E 17:7675218-7675218 0
15 COSM11462 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.388C>G p.L130V 17:7675224-7675224 0
16 COSM6906 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.672+1G>A p.? 17:7674858-7674858 0
17 COSM44219 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.405C>G p.C135W 17:7675207-7675207 0
18 COSM44067 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.721T>A p.S241T 17:7674242-7674242 0
19 COSM11305 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.809T>C p.F270S 17:7673811-7673811 0
20 COSM11658 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>T p.K319* 17:7673573-7673573 0
21 COSM44071 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>G p.K319E 17:7673573-7673573 0
22 COSM44352 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.850A>C p.T284P 17:7673770-7673770 0
23 COSM10889 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 0
24 COSM10758 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
25 COSM10660 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 0
26 COSM10742 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>G p.H193R 17:7674953-7674953 0
27 COSM10777 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.715A>G p.N239D 17:7674248-7674248 0
28 COSM44456 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.668C>A p.P223H 17:7674863-7674863 0
29 COSM43949 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.401T>G p.F134C 17:7675211-7675211 0
30 COSM10645 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 0
31 COSM43935 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.577C>A p.H193N 17:7674954-7674954 0
32 COSM44103 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.737T>A p.M246K 17:7674226-7674226 0
33 COSM10654 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 0
34 COSM10648 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
35 COSM44143 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.919+1G>A p.? 17:7673700-7673700 0
36 COSM43826 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.706T>A p.Y236N 17:7674257-7674257 0
37 COSM44278 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.791T>C p.L264P 17:7673829-7673829 0
38 COSM98254 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.782+1G>A p.? 17:7674180-7674180 0
39 COSM11374 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.752T>A p.I251N 17:7674211-7674211 0
40 COSM44678 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.415A>T p.K139* 17:7675197-7675197 0
41 COSM43947 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 0
42 COSM45544 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.947C>T p.P316L 17:7673581-7673581 0
43 COSM11081 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 0
44 COSM10743 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.848G>C p.R283P 17:7673772-7673772 0
45 COSM43753 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 0
46 COSM44225 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 0
47 COSM43597 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.538G>T p.E180* 17:7675074-7675074 0
48 COSM44808 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.503A>C p.H168P 17:7675109-7675109 0
49 COSM11354 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.991C>T p.Q331* 17:7673537-7673537 0
50 COSM10726 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 0
Sources

Expression for Laryngeal Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Laryngeal Squamous Cell Carcinoma.
Sources

Pathways for Laryngeal Squamous Cell Carcinoma

About this section

Pathways related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 38
Show member pathways
 12.72 CCND1 CDH1 CDKN2A EGFR TP53
2
Pathways in cancer 38
12.57 CCND1 CDH1 CDKN2A EGFR TERT TP53
3
Glioma 38
Show member pathways
 12.5 CCND1 CDH1 CDKN2A EGFR TP53
4
Gastric cancer 38
Show member pathways
 12.4 CCND1 CDH1 CDKN2A EGFR TERT TP53
5
DNA Damage 4
12.36 AURKA CCND1 CDKN2A TP53
6
MicroRNAs in cancer 38
12.31 CCND1 CDKN2A EGFR MIR21 TP53
7
Human T-cell leukemia virus 1 infection 38
12.2 CCND1 CDKN2A TERT TP53
8
Cell cycle 38 1
12.18 CCND1 CDH1 CDKN2A TP53
9
Proteoglycans in cancer 38
12.08 CCND1 EGFR MIR21 TP53
10
Colorectal Cancer Metastasis 65
11.98 CCND1 CDH1 EGFR TP53
11
Integrated Breast Cancer Pathway 1
11.74 AURKA CCND1 CDH1 EGFR TP53
12
Glioblastoma Multiforme 65
11.67 CCND1 CDKN2A EGFR TP53
13
Validated targets of C-MYC transcriptional activation 1
11.63 NME1 TERT TP53
14
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.61 CCND1 CDH1 TERT
15
Regulation of Telomerase 1
11.49 CCND1 EGFR TERT
16
E-cadherin signaling in the nascent adherens junction 1
11.1 CCND1 CDH1 NME1
17
Photodynamic therapy-induced AP-1 survival signaling. 1
10.96 CCND1 CDKN2A EGFR TP53
18
Bladder cancer 1 38
10.88 CCND1 CDH1 CDKN2A EGFR TP53
19
LncRNA-mediated mechanisms of therapeutic resistance 1
10.65 HOTAIR TP53
Sources

GO Terms for Laryngeal Squamous Cell Carcinoma

About this section

Biological processes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 AURKA EGFR MIR21 TERT TP53
2 regulation of protein stability GO:0031647 9.61 AURKA CDKN2A TERT
3 cellular response to drug GO:0035690 9.54 EGFR NME1 TP53
4 liver regeneration GO:0097421 9.43 AURKA CCND1 EGFR
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 EGFR TP53
6 negative regulation of gene expression GO:0010629 9.35 CDKN2B-AS1 HOXA11-AS MIR21 NME1 TERT
7 mitotic G1 DNA damage checkpoint GO:0031571 9.32 CCND1 TP53
8 response to UV-A GO:0070141 9.16 CCND1 EGFR
9 replicative senescence GO:0090399 8.8 CDKN2A TERT TP53

Molecular functions related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.02 AURKA CCND1 CDKN2A EGFR TP53
Sources

Sources for Laryngeal Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....